Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 10, 2025Discover OncologyOpen Access

Transarterial chemoembolization for advanced hepatocellular carcinoma after failure of first-line systemic treatment: a single-center case series

View Full Paper
Ask AI
Bookmark
Share

Authors

QXQingyu XuBLBin LengRYRan You

Discussion

Loading...

Member takes

Overview

Retrospective analysis reveals improved overall survival and response rates for advanced HCC patients, suggesting TACE adds value post systemic treatment failure.

Key Points

  • Overall survival improved significantly, with a median of 24 months reported in patients receiving TACE after systemic treatment failure.
  • Objective response rate was 55.6%, indicating that more than half of the patients responded positively to the treatment.
  • The median time to progression was 3.5 months, accompanied by an acceptable level of treatment-related adverse events.
  • Patients undergoing on-demand TACE alongside systemic treatment achieved disease control in 94.4% of cases.

Cite This Study

Xu et al. (2025) studied this question.

synapsesocial.com/papers/68c1bd2a54b1d3bfb60edf40https://doi.org/10.1007/s12672-025-03363-9
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Role of transarterial chemoembolization for hepatocellular carcinoma with extrahepatic metastases in the era of advancing systemic therapy2024 · 3 citations
  2. 2TACE combined with tislelizumab and lenvatinib in the treatment of intermediate-to-advanced hepatocellular carcinoma: a retrospective real-world study2026
  3. 3Patients with hepatocellular carcinoma (HCC) who require multiple transarterial chemoembolization (TACE) treatments in quick succession and prediction of outcome.2024
  4. 4Transarterial chemoembolization combined with tyrosine kinase inhibitors and programmed death-1 inhibitors in recurrent intermediate and advanced hepatocellular carcinoma: a single-centre retrospective cohort study2026
  5. 5The Efficiency and Safety of Tace Combined with Targeted Therapy and Immunotherapy for Advanced Hepatocellular Carcinoma2026